Literature DB >> 25967696

Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus.

Marcondes Alves B Silva1, Stefany Bruno A Cau1, Rheure Alves M Lopes1, Carla P Manzato1, Karla B Neves1, Thiago Bruder-Nascimento1, Fabiola Leslie Antunes C Mestriner1, Augusto C Montezano2, Aurelie Nguyen Dinh Cat2, Rhian M Touyz2, Rita C Tostes3.   

Abstract

Mineralocorticoid receptors (MRs), which are activated by mineralocorticoids and glucocorticoids, actively participate in mechanisms that affect the structure and function of blood vessels. Although experimental and clinical evidence shows that vascular damage in diabetes is associated with structural alterations in large and small arteries, the role of MR in this process needs further studies. Thus, we tested the hypothesis that MR, through redox-sensitive mechanisms, plays a role in diabetes-associated vascular remodelling. Male, 12-14-weeks-old db/db mice, a model of type 2 diabetes and their non-diabetic counterpart controls (db/+) were treated with spironolactone (MR antagonist, 50 mg/kg/day) or vehicle for 6 weeks. Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice. In addition, spironolactone significantly reduced serum insulin levels, but not aldosterone levels in diabetic mice. Insulin sensitivity, evaluated by the HOMA (homoeostatic model assessment)-index, was improved in spironolactone-treated diabetic mice. Mesenteric resistance arteries from vehicle-treated db/db mice exhibited inward hypertrophic remodelling, increased number of smooth muscle cells and increased vascular stiffness. These structural changes, determined by morphometric analysis and with a myography for pressurized arteries, were prevented by spironolactone treatment. Arteries from vehicle-treated db/db mice also exhibited augmented collagen content, determined by Picrosirius Red staining and Western blotting, increased reactive oxygen species (ROS) generation, determined by dihydroethidium (DHE) fluorescence, as well as increased expression of NAD(P)H oxidases 1 and 4 and increased activity of mitogen-activated protein kinases (MAPKs). Spironolactone treatment prevented all these changes, indicating that MR importantly contributes to diabetes-associated vascular dysfunction by inducing oxidative stress and by increasing the activity of redox-sensitive proteins.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  db/db mice; diabetes; mineralocorticoid receptor; spironolactone; vascular remodelling; vascular stiffness

Mesh:

Substances:

Year:  2015        PMID: 25967696     DOI: 10.1042/CS20140758

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  18 in total

Review 1.  The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease.

Authors:  Jessica L Faulkner; Thiago Bruder-Nascimento; Eric J Belin de Chantemèle
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-03       Impact factor: 2.894

2.  Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta.

Authors:  Brandi M Wynne; Hicham Labazi; Zidonia N Carneiro; Rita C Tostes; R Clinton Webb
Journal:  Eur J Pharmacol       Date:  2017-08-20       Impact factor: 4.432

Review 3.  Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.

Authors:  Guanghong Jia; Annayya R Aroor; Michael A Hill; James R Sowers
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

4.  CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1.

Authors:  Shubhnita Singh; Ariane Bruder-Nascimento; Eric J Belin de Chantemele; Thiago Bruder-Nascimento
Journal:  Biochem Pharmacol       Date:  2021-11-26       Impact factor: 5.858

Review 5.  The Role of Renin-Angiotensin-Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging.

Authors:  Mario Fritsch Neves; Ana Rosa Cunha; Michelle Rabello Cunha; Ronaldo Altenburg Gismondi; Wille Oigman
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-02-23

Review 6.  Novel insight into the dangerous connection between diabetes and heart failure.

Authors:  C Lombardi; V Spigoni; E Gorga; A Dei Cas
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

Review 7.  Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets.

Authors:  Ioannis Akoumianakis; Akansha Tarun; Charalambos Antoniades
Journal:  Br J Pharmacol       Date:  2016-12-14       Impact factor: 8.739

8.  Angiotensin-II activates vascular inflammasome and induces vascular damage.

Authors:  Stefany B Cau; Ariane Bruder-Nascimento; Marcondes B Silva; Fernanda N Z Ramalho; Fabiola Mestriner; Rheure Alves-Lopes; Nathanne Ferreira; Rita C Tostes; Thiago Bruder-Nascimento
Journal:  Vascul Pharmacol       Date:  2021-06-09       Impact factor: 5.738

9.  Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling.

Authors:  Marcondes A B Silva; Thiago Bruder-Nascimento; Stefany B A Cau; Rheure A M Lopes; Fabiola L A C Mestriner; Rafael S Fais; Rhian M Touyz; Rita C Tostes
Journal:  Front Physiol       Date:  2015-10-05       Impact factor: 4.566

10.  Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes.

Authors:  Stine H Finsen; Mie R Hansen; Joachim Hoffmann-Petersen; Henrik F Højgaard; Stefan P Mortensen
Journal:  Physiol Rep       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.